Adherium digital health lists on ASX at 10% premium

Media Release Monsoon Communications Digital health company’s technology improves adherence and patient health in chronic respiratory disease $35m maximum oversubscribed Aust & international institutions & retail investors 26 August 2015: Digital health company Adherium Limited (ASX:ADR) listed on the Australian Securities Exchange today opening at 55 cents per share, a 10 per cent premium to […]

AmpliPhi Biosciences Announces Approval of Common Stock Listing on NYSE MKT

San Diego and Richmond, VA, USA, Ljubljana, Slovenia, and Sydney, Australia, August 18, 2015 Link here. AmpliPhi Biosciences Corporation (OTCQB: APHBD), a global leader in developing bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced that its shares of common stock have been approved for listing on the NYSE MKT, subject to continued satisfaction of […]

Adherium $35m ASX IPO to expand sales of digital health technology to improve medication adherence

–          Digital health company’s technology proven to improve adherence and patient health in chronic respiratory disease –          $25.85m in signed commitments, AstraZeneca US$3m cornerstone investment; led Bell Potter Securities –          First-in-class 10 year Supply and Development Agreement with AstraZeneca –          Technology has been used in 40 projects, across 29 countries, with 32 publications referencing Smartinhaler 5 August 2015 […]

AmpliPhi BioSciences Cleared to Submit Listing Application to NYSE MKT

Company Announces One-for-Fifty Reverse Stock Split Shares of Common Stock Will Begin Trading on a Split-Adjusted Basis on August 07, 2015 San Diego and Richmond, VA, USA, Ljubljana, Slovenia, and Sydney, Australia, August 04, 2015 –Linkhere. AmpliPhi BioSciences Corporation (OTCQB: APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug resistant infections, today […]